## Abstract We describe a 52βyearβold man with paroxysmal nocturnal hemoglobinuria (PNH) and a moderate transfusion requirement. Prior to and during sequential therapy with androgen (metenolone), glucocorticoid, and danazol, we evaluated CD59βnegative expression (PNH clone) in red blood cells, neut
Danazol for paroxysmal nocturnal hemoglobinuria
β Scribed by Harrington, William J.; Kolodny, Luciano; Horstman, Lawrence L.; Jy, Wenche; Ahn, Yeon S.
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 45 KB
- Volume
- 54
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
β¦ Synopsis
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patients refractory to glucocorticoids and requiring blood transfusions, an alternative therapy is needed. We studied danazol therapy in 5 patients refractory to other treatments. Four of the 5 benefited, showing rise in hematocrit and eventual cessation of transfusion requirements. Remissions lasted Υ2 years in 3 and 10 years in 1 patient. Danazol was well-tolerated without serious side effects. Danazol appears to be a good alternative treatment in PNH.
π SIMILAR VOLUMES
A case of a patient who developed erythroleukemia 3 years into the course of paroxysmal nocturnal hemoglobinuria (PNH) is presented. A case of erythroleukemia with a positive sucrose lysis test has been reported, but our case appears to be the first with a long clinical course of PNH evolving into e